Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western hemisphere. Both the Rai and Binet staging systems have been important clinical tools for predicting outcomes of this heterogeneous disease. In the past 10 years, an explosion of research using newer techniques has helped us to learn more about the molecular biology of CLL and the impact it has on prognosis. In tandem with this increased knowledge on the molecular level, the menu of treatment options has improved significantly.
CLL is commonly found when an absolute lymphocytosis is discovered in an entirely asymptomatic person. Other patients notice some degree of painless lymphadenopathy and consult a physician. A minority of patients present with typical B symptoms of lymphoma (weakness, night sweats, weight loss, or fever). Finally, some patients present with an infection or autoimmune phenomenon (such as hemolytic anemia) related to immune dysfunction.
The threshold for diagnosing CLL was originally 5,000 lymphocytes/µL. A recent update of the 1996 National Cancer Institute–Working Group requires the presence of 5,000 B lymphocytes/µL (past guidelines did not specify B lymphocytes). Examination of the peripheral blood smear should reveal many small morphologically mature lymphocytes with a narrow border of cytoplasm and a dense nucleus. Flow cytometry must demonstrate clonality, as determined by kappa or lambda light chain restriction, with CD19, CD20, CD23, and CD5 coexpression. Surface membrane immunoglobulin and CD20 are typically dim. Most other types of B-cell lymphoproliferative disorders are associated with high expression of surface membrane immunoglobulin and cells that do not express CD5. The exception is mantle cell lymphoma, which expresses CD5 but usually can be distinguished from CLL by lack of CD23 positivity and an overexpression of cyclin D1.
A bone marrow biopsy is not required for the diagnosis of CLL. However, if performed, it will show either hyper- or normocellularity, with a nodular or diffuse pattern of lymphocytic infiltration representing more than 30% of all nucleated cells. Prognostic tests such as molecular genetics, fluorescence in situ hybridization (FISH), mutational status of immunoglobulin heavy chain genes, and expression of ZAP-70 or CD38 are not required for the diagnosis of CLL.
Biology and Prognostic Markers
Rai and Binet Staging
Until recently, the prognosis of patients with CLL was based solely on clinical stage. Two staging systems, Rai and Binet, are used to describe extent of disease and portend prognosis.[3,4] In the series published by Rai and colleagues, median survival from time of diagnosis ranged from 150 months for stage 0 patients to only 19 months for those with stage III and IV disease. Binet and colleagues categorized patients as low risk (stage A), intermediate risk (stage B) and high risk (stage C), which correspond, respectively, to Rai stage 0, I or II, and III or IV.
The staging systems are most useful in predicting outcomes in patients with advanced disease (Rai stage III/IV or Binet stage C). Patients in the low- and intermediate-risk groups have a varied clinical course that may ultimately prove to be indolent or aggressive. New prognostic factors have allowed some degree of predictability of disease course in these patients with early-stage disease, and have also shed light on the biology of CLL growth.
1. Cheson BC, Bennett JM, Grever M, et al: National Cancer Institute–sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996.
2. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute–Working Group (NCI-WG) 1996 guidelines. Blood 111:5446-5456, 2008.
3. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975.
4. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981.
5. Damle RN, Wasil T, Fais F, et al: Immunoglobulin V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1848-1854, 1999.
6. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999.
7. Crespo M, Bosch F, Villamor V, et al: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003.
8. Rassenti LZ, Huynh L, Toy TL, et al: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:1910-1916, 2004.
9. Del Principe MI, Del Poeta G, Buccisano F, et al: Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 108:853-861, 2006.
10. Hamblin T, Orchard J, Ibbotson R, et al: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029, 2002.
11. Krober A, Seiler T, Benner A, et al: VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002.
12. Dohner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000.
13. Grever M, Lucas D, DeWald G, et al: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup phase III trial E2997. J Clin Oncol 25:799-804, 2007.
14. Stilgenbauer S, Dohner K, Dohner H, et al: Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia. Ann Hematol 76:101-110, 1998.
15. Sturm I, Bosanquet AG, Hermann S, et al: Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477-484, 2003.
16. Lozanski G, Heerema NA, Flinn I, et al: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281, 2004.
17. Gribben J: Molecular profiling in CLL. American Society of Hematology Education Program Book, pp 444-449, 2008.
18. Wierda WG, O’Brien S, Wang X, et al: Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109:4679-4685, 2007.
19. Rassenti LZ, Jain S, Keating MJ, et al:Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112:1923-1930, 2008.
20. Rai KR: The role of molecular markers for predicting treatment outcomes in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7(3 suppl 8):6-8, 2009.
21. Dighiero G, Maloum K, Desablens B, et al: Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338:1506-1514, 1998.
22. Shustik C, Mick R, Silver R, et al: Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hematol Oncol 6:7-12, 1988.
23. Montserrat E, Fontanillas M, Estape J, for the Spanish PETHEMA Group: Chronic lymphocytic leukemia treatment: an interim report of PETHEMA trials. Leuk Lymphoma 5:89-92, 1991.
24. CLL Trialists’ Collaborative Group: Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials. J Natl Cancer Inst 91:861-868, 1999.
25. Raphael B, Andersen JW, Silber R, et al: Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 9:770-776, 1991.
26. Jaksic B, Brugiatelli M, Krc I, et al: Comparison of high-dose chlorambucil versus Binet’s modified CHOP regimen in B-cell chronic lymphocytic leukemia in advanced phase: results of an international multicentric randomized trial. Cancer 79:2107-2114, 1997.
27. French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 75:1422-1425, 1990.
28. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000.
29. Eichhorst BF, Busch R, Stauch M, et al: Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a phase III study of the German CLL Study Group (GCLLSG) (abstract 369). Blood 102:109a, 2003.
30. Leporrier M, Chevret S, Cazin B, et al: Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319-2325, 2001.
31. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomized trial of fludarabine vs cyclophosphamide, doxorubicin, and prednisone (CAP) for the treatment of advanced stage chronic lymphocytic leukemia. Lancet 347:1432-1438, 1996.
32. Robak T: Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 40:551-564, 2001.
33. Robak T, Blonski JZ, Kasznicki M, et al: Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 3:244-250, 2002.
34. Weiss MA, Maslak PG, Jurcic JG, et al: Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21:1278-1284, 2003.
35. Kay NE, Geyer SM, Lin T, et al: Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia (abstract 339). Blood 104:100a, 2004.
36. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007.
37. Knauf WU, Lissichkov T, Aldaoud A, et al, Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009.
38. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-803, 2007.
39. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006.
40. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): A randomized controlled trial. Lancet 370:230-239, 2007.
41. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
42. Huhn D, von Schilling C, Wilhelm M, et al: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326-1331, 2001.
43. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001.
44. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:
45. Manshouri T, Do KA, Wang X, et al: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 1:2507-2513, 2003.
46. O’Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001.
47. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002.
48. Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in Bcell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979, 2005.
49. Stilgenbauer S, Winkler D, Krober A, et al: Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG) (abstract 478). Blood 104, 2004.
50. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007.
51. Keating M, Coutré S, Rai K, et al: Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 4:220-227, 2004.
52. O’Brien SM, Keating MJ, Mocarski ES: Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7:125-130, 2006.
53. Rawstron A, Kennedy B, Evans P: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:29-35, 2001.
54. Maloum K, Sutton L, Baudet S: Novel flow cytometric analysis based on BCD5 + subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukemia. Br J Hematol 119:970-975, 2002.
55. Provan D, Bartlett-Pandite L, Zwicky C, et al: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88:2228-2235, 1996.
56. Wendtner C-M, Ritgen M, Schweighofer CD, et al: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093-1101, 2004.
57. Lin TS, Donohue KA, Lucas MS, et al: Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101 (abstract 755). Blood 110, 2007.
58. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003.
59. Byrd JC, Rai KR, Peterson BL, et al: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005.
60. Keating MJ, O’Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005.
61. Tam CS, O’Brien S, Wierda W, et al: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008.
62. Hallek M, Fingerle-Rowson G, Fink AM, et al: Immunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) with advanced chronic lymphocytic leukemia (CLL) (abstract 325). Blood 112, 2008.
63. Robak T, Moiseev S, Dmoszynska A, et al: Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia compared with FC alone: final results from the international randomized phase III REACH trial (abstract 1). Blood 112, 2008.
64. Lamanna N, Kalaycio M, Maslak P, et al: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575-1581, 2006.
65. Reynolds C, Di Bella N, Lyons R, et al: Phase III trial of fludarabine, cyclophosphamide, and rituximab vs pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia (abstract 327). Blood 112, 2008.
66. Chanan-Khan MK, Whitworth A, Lawrence D, et al: Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial. Leuk Lymphoma 48:S166, 2007.
67. Ferrajoli A, O’Brien S, Faderl SH, et al: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297, 2008.
68. Chen C, Harminder P, Xu W, et al: A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL) (abstract 44). Blood 112, 2008.
69. Osterborg A, Kipps TJ, Mayer J, et al: Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludara-bine and alemtuzumab or bulky fludarabine refractory disease: Results from the planned interim analysis of an international pivotal trial. Blood 112:328, 2008.
70. Byrd JC, Castro JE, Flinn IW, et al: Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphoctyic leukemia (CLL): Results from a phase I/II multicenter study (abstract 7003). J Clin Oncol 26:372s, 2008.
71. Lin TS, Heerema NA, Lozanski G, et al: Flavopiridol (Alvocidib) induces durable responses in relapse chronic lymphoctic leukemia (CLL) patients with high-risk cytogenetic abnormalities (abstract 46). Blood 112, 2008.
72. Wierda W, O’Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005.
73. Frankfurt O, Hamilton E, Duffey S, et al: Alemtuzumab and rituximab combination therapy for patients with untreated CLL—a phase II trial (abstract 2098). Blood 112, 2008.
74. Faderl S, Thomas DA, O’Brien S, et al: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413-3415, 2003.
75. Fischer K, Stilgenbauer S, Schweighofer CD, et al: Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trial of the German CLL Study Group (GCLLSG) (abstract 330). Blood 112, 2008.
76. Wierda W, Faderl S, O’Brien S, et al: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL (abstract 340). Blood 104:101a, 2004.
77. Gribben JG, Zahrieh D, Stephans K, et al: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106:4389-4396, 2005.
78. Brown JR, Kim HT, Li S, et al: Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12:1056-1064, 2006.
79. Dreger P, Corradini P, Kimby E, et al: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:12-17, 2006.